Clinical platform trials for coronavirus (COVID-19) treatments - GOV.UK
The COVID-19 Antivirals and Therapeutics Taskforce closed on 31 March 2023, aligning with the government's strategy to live with COVID-19. Clinical trials, including phases 1, 2, and 3, are crucial for discovering effective treatments. The UK has established clinical trial platforms like AGILE, RECOVERY, REMAP-CAP, PRINCIPLE, PROTECT-V, HEAL-COVID, STIMULATE-ICP, and PANORAMIC to test and implement COVID-19 treatments. These trials aim to improve patient outcomes, reduce hospital admissions, and enhance recovery, with some treatments already proven effective and integrated into NHS care.
Reference News
The COVID-19 Antivirals and Therapeutics Taskforce closed on 31 March 2023, aligning with the government's strategy to live with COVID-19. Clinical trials, including phases 1, 2, and 3, are crucial for discovering effective treatments. The UK has established clinical trial platforms like AGILE, RECOVERY, REMAP-CAP, PRINCIPLE, PROTECT-V, HEAL-COVID, STIMULATE-ICP, and PANORAMIC to test and implement COVID-19 treatments. These trials aim to improve patient outcomes, reduce hospital admissions, and enhance recovery, with some treatments already proven effective and integrated into NHS care.